Lalani, A.-K.A. et al. 2017. First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience. Canadian Urological Association Journal. 11, 3-4 (Apr. 2017), 112–7. DOI:https://doi.org/10.5489/cuaj.4398.